Cormorant

Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders

Retrieved on: 
Thursday, February 8, 2024
SAN, Massachusetts General Hospital, Immunosuppression, Hospital, Cell, History, Seizure, Clinical trial, Column, Patient, American Epilepsy Society, DSM-IV codes, UC, Symbiosis, Investment, Nervous system, Harvard Medical School, Phase, Therapy, Cormorant, Annual general meeting, Pharmaceutical industry

Proceeds from the financing will be used to advance the company’s pipeline of wholly-owned, off-the-shelf cell therapies for multiple indications, including its lead investigational candidate, NRTX-1001.

Key Points: 
  • Proceeds from the financing will be used to advance the company’s pipeline of wholly-owned, off-the-shelf cell therapies for multiple indications, including its lead investigational candidate, NRTX-1001.
  • “Neurona has pioneered development of a fully-differentiated cell therapy for drug-resistant focal epilepsy that is designed to be disease-modifying, repairing the affected neural network, and is yielding very promising initial clinical data.
  • It signifies the conviction that Neurona’s cell therapies have the potential to transform the treatment of previously refractory, devastating neurological disorders.
  • These subjects received a one-time administration of NRTX-1001 as well as temporary immunosuppression to promote the long-term persistence of the cell therapy.

8 Rivers Announces Cormorant Clean Energy Project, the First Commercial Deployment of 8RH2 Ultra-Low Carbon Hydrogen Technology

Retrieved on: 
Tuesday, January 9, 2024
Hydrogen, CO2, Aviation, Head, Ammonia, Cormorant, Power, Agriculture, Ship, Environment, Carbon, Transport, Workforce, River, Growth, Renewable energy

The Cormorant project will be powered by 8 Rivers’ proprietary 8RH2 hydrogen process, representing the first commercial deployment of the technology.

Key Points: 
  • The Cormorant project will be powered by 8 Rivers’ proprietary 8RH2 hydrogen process, representing the first commercial deployment of the technology.
  • 8RH2 is an ultra-low-carbon hydrogen process that harnesses oxy-combustion to eliminate CO2 emissions and lower costs.
  • “The Cormorant Clean Energy Project is the ideal location to deploy our 8RH2 platform commercially, at scale for the first time,” said Steve Milward, Chief Operating Officer at 8 Rivers.
  • 8RH2 provides the key to scaling ultra-low-carbon hydrogen and ammonia production to industrial production scale at Cormorant.

Fluor Selected to Provide Front-End Engineering and Design for Low-Carbon Blue Ammonia Facility

Retrieved on: 
Thursday, October 5, 2023
Chemicals, Plastics, Alternative Energy, Energy, Green Technology, Manufacturing, Sustainability, Technology, Other Natural Resources, Environment, Natural Resources, Other Technology, Science, Other Energy, Other Science, Engineering, Multimedia, NYSE, FLR, Cormorant, FEED, Ammonia, Carbon, Fluor Corporation, River, Corporation, Hydrogen, Methanol, Pine River Capital Management, Fluor

Fluor Corporation (NYSE: FLR) announced today that it has been awarded a contract for front-end engineering and design (FEED) and procurement services by Cormorant Clean Energy, LLC – a subsidiary of 8 Rivers Capital, LLC – for the construction of a low-carbon blue ammonia production facility.

Key Points: 
  • Fluor Corporation (NYSE: FLR) announced today that it has been awarded a contract for front-end engineering and design (FEED) and procurement services by Cormorant Clean Energy, LLC – a subsidiary of 8 Rivers Capital, LLC – for the construction of a low-carbon blue ammonia production facility.
  • (Photo: Business Wire)
    Once constructed, the facility will be the first commercial-scale application of 8 Rivers’ 8RH2 ultra-low-carbon hydrogen production technology.
  • The facility’s ammonia will be considered ‘blue’ because more than 99% of the carbon dioxide generated will be captured as part of the process.
  • The project includes multiple licensed technology units which Fluor will develop deliverables for using process design packages from the licensors.

Nexo Therapeutics Launches With $60 Million Series A Financing

Retrieved on: 
Wednesday, July 26, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Yale University, University of Colorado School of Medicine, Broad Institute, Versant, University, Therapy, Cormorant, Head, Biogen, Roche, Cancer, Research, Cysteine, MIT, Harvard University, AstraZeneca, Astex Pharmaceuticals, Proteomics, MD Anderson Cancer Center, Biochemistry, Development, ARIAD Pharmaceuticals, NEA, C4, Alkermes, Patient, Associate, Drug discovery, Vertex Pharmaceuticals, Biology, MDL Information Systems, LP, New Enterprise Associates, Pharmacology, Nested, Disease, Pharmaceutical industry, Fine chemical, Nexø, Chemistry

Nexo Therapeutics today emerged from stealth with a $60 million Series A financing led by founding investor Versant Ventures with participation from New Enterprise Associates and Cormorant Asset Management.

Key Points: 
  • Nexo Therapeutics today emerged from stealth with a $60 million Series A financing led by founding investor Versant Ventures with participation from New Enterprise Associates and Cormorant Asset Management.
  • “At Nexo, we are leveraging innovations in covalent chemistry and chemical biology to enable targeting these fundamental drivers.
  • Prior to joining Nexo, he served as Head of Discovery Biology at Nested Therapeutics where he helped build a precision oncology pipeline.
  • He has led the creation of corporate headquarters for multiple emerging biotechs and prior to joining Nexo, he held senior leadership roles at Proteovant Therapeutics, Jnana Therapeutics and C4 Therapeutics.

Expansion Therapeutics Appoints Raymond Kelleher, M.D., Ph.D., to its Board of Directors

Retrieved on: 
Wednesday, October 26, 2022
Health, Neurology, Clinical Trials, Research, Science, Biotechnology, Pharma, Cell biology, Doctor of Philosophy, Therapy, Cormorant, Growth, Hospital, Neurodegeneration, Scripps Research, Cognition, Biotechnology, Biology, RNA, Research, PNAS, Massachusetts General Hospital, Multimedia, Harvard Medical School, Dementia, Internal medicine, Ruth Shonle Cavan Young Scholar Award, Harvard University, Industry, Neurology, National, Board, Biomedical sciences, Faculty, Board of directors, Nobel, Literature, Intellectual property, Massachusetts Institute of Technology, Leadership, Pharmaceutical industry, Vaccine, Technology, Stanford University, Nature, Expansion

Expansion Therapeutics, Inc., a biotechnology company focused on developing transformative oral medicines for severe RNA-mediated diseases, today announced the appointment of Raymond J. Kelleher, M.D., Ph.D., to its Board of Directors representing Cormorant Asset Management.

Key Points: 
  • Expansion Therapeutics, Inc., a biotechnology company focused on developing transformative oral medicines for severe RNA-mediated diseases, today announced the appointment of Raymond J. Kelleher, M.D., Ph.D., to its Board of Directors representing Cormorant Asset Management.
  • Scott Rocklage, Ph.D., Board Chairman added, We look forward to collaborating with Dr. Kelleher and benefiting from his extensive board and leadership experience at both large and small innovative pharmaceutical and biotech companies.
  • He represents Cormorant on the boards of Arkuda Therapeutics, BiVACOR, and ONK Therapeutics as director, and Chroma Therapeutics, Umoja Biopharma, Interius BioTherapeutics, Garuda Therapeutics, and DTx Pharma as board observer.
  • Expansion Therapeutics is a biotechnology company focused on developing transformative oral medicines for severe RNA-mediated diseases including neurodegenerative disorders.

MoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp.

Retrieved on: 
Tuesday, April 5, 2022
Company, Moonlake, Therapy, Leadership, Forward-looking statement, Board, TM, Psoriatic arthritis, Research, SEC, Failure, CEO, Board of directors, Tissue, Joint, Private Securities Litigation Reform Act, Hidradenitis suppurativa, Inflammation, Technology, Director, U.S. Securities and Exchange Commission, Business architecture, Ankylosing spondylitis, Hidradenitis, Helix, A/F, Founder CEO, Acquisition, Patient, SM, Cormorant, Online gambling, Pharmaceutical industry, Management, Risk management, Nasdaq

MoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp.

Key Points: 
  • MoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp.
    MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company elevating care with innovative immunology therapeutics, will be listed on Nasdaq under the ticker MLTX
    ZUG, Switzerland and Boston, U.S., April 5, 2022 MoonLake Immunotherapeutics AG, a clinical-stage biopharmaceutical company elevating care with innovative immunology therapeutics, today announced the closing of its previously announced business combination with Helix Acquisition Corp. (Helix), a publicly traded special purpose acquisition company The business combination was unanimously approved by Helixs board of directors and was approved by Helixs shareholders at an extraordinary general meeting on March 31, 2022.
  • In connection with the closing, Helix changed its name to MoonLake Immunotherapeutics (MoonLake or the Company).
  • Dr. JorgeSantos da Silva, Founder & CEO of MoonLake, added: Listing on the Nasdaq Stock Market is a major achievement for the MoonLake team and its investors.
  • MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, the first investigational Nanobody for the treatment of inflammation, to revolutionize outcomes for patients.

ENLIVEN THERAPEUTICS PROVIDES CORPORATE UPDATE ON FINANCING, EXPANSION OF BOARD AND LEADERSHIP TEAM

Retrieved on: 
Wednesday, January 19, 2022
Janus, Survival, Patient, Chemistry, Board of directors, MBA, Amgen, Breakthrough therapy, Five-prime cap, Therapy, Company, Cormorant, Cancer, Director, Board, Acquisition, Pharmaceutical industry, Security (finance), Management, Citadel

BOULDER, Colo., Jan. 19, 2022 /PRNewswire/ -- Enliven Therapeutics, Inc. ("Enliven" or the "Company"), a precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today provided a corporate update onthe close of an $85 million Series B financing, additions to the Board of Directors, and expansion of the Company's leadership team.

Key Points: 
  • BOULDER, Colo., Jan. 19, 2022 /PRNewswire/ -- Enliven Therapeutics, Inc. ("Enliven" or the "Company"), a precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today provided a corporate update onthe close of an $85 million Series B financing, additions to the Board of Directors, and expansion of the Company's leadership team.
  • All existing investors participated in the round and new investors included Boxer Capital, Janus Henderson Investors, and Logos Capital.
  • Dr. Collins joins Enliven as a board-certified oncologist after serving as Chief Medical Officer at Five Prime Therapeutics through its acquisition by Amgen.
  • "Enliven has made rapid progress in developing their pipeline of potentially best-in-class therapeutics and built a stellar leadership team to support their vision," said Andy Phillips, Managing Director at Cormorant.

Cormorant Utility Services and Métis Infinity Investments LP Announce the Creation of 'Cormorant Infinity Power Solutions Ltd.'

Retrieved on: 
Friday, December 17, 2021
Paragon, Solution, Indigenous peoples, Ownership, Sale, MNO, JV, Cormorant, Time, PowerTel, CEO, Safety, Investment, GLOBE, Mining, Partnership, Employment, First Nations, Renewable energy, Management, Infinity

CAMBRIDGE, Ontario, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Cormorant Utility Services (Cormorant), a leading provider of comprehensive solutions to the utility power sector, has partnered with Mtis Infinity Investments LP (Infinity LP), a resilient Mtis business and investment hub, to create a strategic joint venture - Cormorant Infinity Power Solutions.

Key Points: 
  • CAMBRIDGE, Ontario, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Cormorant Utility Services (Cormorant), a leading provider of comprehensive solutions to the utility power sector, has partnered with Mtis Infinity Investments LP (Infinity LP), a resilient Mtis business and investment hub, to create a strategic joint venture - Cormorant Infinity Power Solutions.
  • Scott Patles-Richardson, CEO and Director of Mtis Infinity Investments LP, stated:"We believe our partnership represents the transformative potential of Indigenous economic reconciliation.
  • Mtis Infinity Investments is parent to the following subsidiaries: Infinity Equipment Rentals, Thompson Infinity, NorCan Infinity LP, TNT Infinity Crane and Rigging, AlumaSafway Infinity, BrandSafway Infinity, Midlite Infinity, Paragon Infinity, Powell Infinity, and Terracon Infinity.
  • Cormorant Utility Services - Fiona Blondin; Director of Indigenous Strategies ( [email protected] )
    Mtis Infinity Investments LP (Infinity LP) - Dan Courville; Regional Manager ( [email protected] )

Expansion Therapeutics Raises $80 Million Series B Financing to Treat Neurodegenerative Diseases

Retrieved on: 
Wednesday, September 29, 2021
Professional Services, Health, Genetics, Finance, Research, Science, Biotechnology, Therapy, DM1, Neurodegeneration, Oral medicine, Observation, RNA, Doctor of Philosophy, Amyotrophic lateral sclerosis, Patient, Rapunzel's Tangled Adventure (season 2), Expansion, Tauopathy, Lists of diseases, Palsy, Program, Scripps Research, Disease, Leadership, Genetics, American Chemical Society, Science, ALS, Research, FTD, Neuroscience, Frontotemporal dementia, Intellectual property, Cormorant, Venture, Pharmaceutical industry, Vaccine

Expansion Therapeutics, Inc., a biotechnology company focused on developing transformative oral medicines for severe RNA-mediated diseases, today announced the close of an $80 million Series B financing.

Key Points: 
  • Expansion Therapeutics, Inc., a biotechnology company focused on developing transformative oral medicines for severe RNA-mediated diseases, today announced the close of an $80 million Series B financing.
  • Expansion focuses on structured RNA targets that are evolutionarily conserved or genetically demonstrated to cause disease.
  • Expansion is focused on neurological diseases where few treatment options are available for patients such as DM1 which is a system wide disorder affecting muscle, cardiac and brain function.
  • Expansion Therapeutics is a biotechnology company focused on developing transformative oral medicines for severe RNA-mediated diseases including neurodegenerative disorders.

858 Therapeutics Launches with Proven Team and $60 Million Series A Financing

Retrieved on: 
Tuesday, September 21, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Biotechnology, Amira, Therapy, Cancer, Gene expression, Record, Protein, Inflammation, RNA, NEA, Patient, Versant, Genentech, Bristol Myers Squibb, Cormorant, Biology, Initial public offering, Series A round, CA, Technology, IPO, VP, Fine chemical, Pharmaceutical industry, Vaccine, 858 Therapeutics, Versant Ventures, NEA, 858 THERAPEUTICS, VERSANT VENTURES, NEA

858 Therapeutics today exited stealth mode with a $60 million Series A financing led by founding investor Versant Ventures, with participation from NEA, Cormorant Asset Management and Logos Capital.

Key Points: 
  • 858 Therapeutics today exited stealth mode with a $60 million Series A financing led by founding investor Versant Ventures, with participation from NEA, Cormorant Asset Management and Logos Capital.
  • 858s founding team includes CEO Jeffrey Stafford, Ph.D., CSO James Veal, Ph.D., and VP of Biology Gretchen Bain, Ph.D.
  • They previously held leadership roles at three other San Diego-based discovery companies co-founded by Versant including Jecure Therapeutics, Quanticel Pharmaceuticals and Amira Pharmaceuticals.
  • With this financing, the company plans to expand its team to about 40 people within the next 18 months.